Key result
Transvenous ICDs carry a 1.9% infection rate, predicted by dialysis, complicated diabetes, and younger age.
Why the study?
Recent guidelines highlighted the need to better identify patients at high risk of cardiac device infection after ICD placement to assist in device selection.
What is the prevalence of and risk factors for device-related infection in Medicare patients undergoing de novo transvenous ICD implantation?
Cohort (n=26,742)
Yes
What is the prevalence of and risk factors for device-related infection in Medicare patients undergoing de novo transvenous ICD implantation?
In a large Medicare cohort, the rate of de novo transvenous ICD infection was 1.9% at 2 years, with higher risk observed in younger patients (<70 years), those on dialysis, and those with complicated diabetes.
No takes yet. Share an insight, caveat, or question.
Real-world Medicare data quantify de novo ICD infection rates and predictors; leaves open whether targeted prevention alters outcomes in high-risk subgroups.
El‐Chami et al. (2021) conducted a cohort in De novo transvenous implantable cardioverter-defibrillator (TV-ICD) placement (n=26,742). De novo transvenous implantable cardioverter-defibrillator (TV-ICD) implantation was evaluated on Infection within 720 days of implantation. Among Medicare patients undergoing de novo transvenous ICD implantation, the rate of device-related infection within 720 days was 1.9%, with age <70 years, dialysis, and complicated diabetes as predictors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: